首页> 外文OA文献 >Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

【2h】

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

机译：每周一次的GLP-1受体激动剂阿比鲁肽（HARMONY 2）的功效和安全性：52周主要终点来自一项随机，安慰剂对照试验，该试验针对饮食和运动控制不足的2型糖尿病患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Michael A. Nauck; Murray W. Stewart; Christopher Perkins; Angela Jones-Leone; Fred Yang; Caroline Perry; Rickey R. Reinhardt; Marc Rendell;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52?week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [J] . Michael A. Nauck, Murray W. Stewart, Christopher Perkins, Diabetologia: clinical and experimental diabetes and metabolism . 2015,第2期

机译：每周一次的GLP-1受体激动剂阿比鲁肽（HARMONY 2）的功效和安全性：52周的主要终点来自一项饮食控制和运动控制不充分的2型糖尿病患者的随机安慰剂对照试验
2. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin [J] . Reusch J., Stewart M. W., Perkins C. M., Diabetes, obesity & metabolism . 2014,第12期

机译：每周一次的胰高血糖素样肽1受体激动剂阿比鲁肽的有效性和安全性（HARMONY 1试验）：52周主要终点来自一项随机，双盲，安慰剂对照试验，该试验针对不受吡格列酮控制的2型糖尿病患者，有或没有二甲双胍
3. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial [J] . Kaku K., Enya K., Nakaya R., Diabetes, obesity & metabolism . 2015,第7期

机译：在饮食和运动控制不充分的日本2型糖尿病患者中，G蛋白偶联受体40激动剂Fasiglifam（TAK-875）的疗效和安全性：一项随机，双盲，安慰剂对照的III期临床试验
4. A randomized placebo-controlled trial of pioglitazone to improve metabolic control in adolescents with type 1 diabetes mellitus. [D] . Zdravkovic, Vera. 2005

机译：吡格列酮对改善1型糖尿病青少年的代谢控制的随机安慰剂对照试验。
5. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [O] . Michael A. Nauck, Murray W. Stewart, Christopher Perkins, -1

机译：每周一次的GLP-1受体激动剂阿比鲁肽（HARMONY 2）的功效和安全性：52周主要终点来自一项随机安慰剂对照试验该试验针对饮食和运动控制不足的2型糖尿病患者
6. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial [O] . Smits, Mark M, Tonneijck, Lennart, Muskiet, Marcel H A, 2017

机译：GLP-1受体激动剂在2型糖尿病患者中的心率加速：一项急性和12周随机，双盲，安慰剂对照试验

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

著录项

相似文献

相关主题

期刊订阅